Saturday 17 October 2026
Export GEHC’s income statement to Excel — free account
GE HealthCare Technologies Inc.
GEHC Healthcare Medical Devices
GE HealthCare Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 billion, up 4.84% from fiscal 2024. In the quarter to June 2026, revenue grew 5.75%, EPS grew 17.0%, free cash flow grew 750.0% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for three consecutive years, revenue growth for five; insiders bought in the last twelve months.
69.57
0.78
−1.11%
Follow GEHC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
15.48 | 17.99 | 17.03 | 14.68 |
P/S ratio |
1.69 | 1.81 | 1.55 | 1.36 | |
P/FCF ratio |
24.46 | 24.85 | 21.37 | 18.36 | |
P/Operating CF |
57.75 | 35.62 | 111.92 | 172.60 | |
P/B ratio |
3.42 | 3.60 | 3.04 | 2.64 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.08 | 2.16 | 1.99 | 1.81 | |
EV/EBITDA |
12.71 | 13.34 | 12.86 | 11.50 | |
EV/Operating CF |
22.73 | 22.42 | 20.58 | 18.29 | |
EV/FCF |
30.03 | 29.61 | 27.47 | 24.33 | |
Quick Ratio |
0.77 | 0.93 | 0.71 | 0.72 | |
Current Ratio |
1.18 | 1.37 | 1.22 | 1.26 | |
Net Debt/EBITDA |
9.75 | 7.34 | 13.87 | 10.49 | |
Debt/Assets |
32.73% | 31.62% | 31.12% | 30.96% | |
Debt/Equity |
1.18 | 1.12 | 1.08 | 1.05 | |
Asset Turnover |
0.58 | 0.59 | 0.59 | 0.58 | |
Operating CF/Net income |
1.33 | 1.79 | 0.75 | 0.30 | |
Capex/Depreciation |
(0.74) | (0.92) | (1.16) | (0.62) | |
Research and Development Expense of Revenue |
5.68% | 5.65% | 6.72% | 6.10% | |
Selling, General and Administrative Expense of Revenue |
20.32% | 19.50% | 21.77% | 21.11% | |
Intangible Assets out of Total Assets |
0.40 | 0.40 | 0.46 | 0.46 | |
Share Based Compensation of Revenue |
0.74% | 0.63% | 0.68% | 0.85% | |
Graham Net Nets |
(0.42) | (0.37) | (0.49) | (0.54) | |
Graham Number |
48.96 | 48.35 | 46.94 | 48.78 | |
Earnings Yield |
6.46% | 5.56% | 5.87% | 6.81% | |
Free Cash Flow Yield |
4.09% | 4.02% | 4.68% | 5.45% | |
Revenue per Share |
11.28 | 12.50 | 11.25 | 11.69 | |
Operating CF per Share |
1.30 | 2.30 | 0.64 | 0.37 | |
Capex per Share |
(0.24) | (0.29) | (0.39) | (0.22) | |
Free Cash Flow per Share |
1.06 | 2.01 | 0.25 | 0.15 | |
Cash per Share |
8.83 | 9.89 | 5.01 | 4.65 | |
Shareholders Equity per Share |
21.96 | 22.79 | 23.42 | 24.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
21.96 | 22.79 | 23.42 | 24.26 | |
Free Cash Flow |
483.00 | 916.00 | 112.00 | 68.00 | |
Working Capital |
1,820.00 | 3,396.00 | 1,897.00 | 2,195.00 | |
Capital Expenditures |
(110.00) | (134.00) | (178.00) | (100.00) | |
Net Current Asset Value |
(14,218.00) | (14,015.00) | (16,019.00) | (15,760.00) | |
EV/EBIT |
15.37 | 16.13 | 15.75 | 14.05 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.02 | |
Price to Operating Income |
12.52 | 13.54 | 12.25 | 10.60 | |
| Other line items | |||||
Average Receivables |
3,579.00 | 3,760.50 | 3,679.00 | 3,721.50 | |
Average Payables |
2,949.00 | 3,142.50 | 3,281.00 | 3,103.00 | |
Average Inventory |
2,214.00 | 2,086.50 | 2,255.50 | 2,383.00 | |
Average Assets |
34,991.00 | 34,997.50 | 35,355.50 | 36,373.00 | |
Average Common Equity |
9,176.50 | 9,427.50 | 9,944.50 | 10,361.50 |
Columns are period end dates